跳至主要内容
临床试验/NCT01198899
NCT01198899已完成不适用

Belgian Screening Project for the Detection of Anderson-Fabry Disease in Hypertrophic Cardiomyopathy

University Hospital, Ghent9 个研究点 分布在 1 个国家目标入组 540 人开始时间: 2009年7月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
540
试验地点
9
主要终点
Determination of the prevalence of Fabry mutations in patients with left ventricular hypertrophy (moderate to severe), as measured by echocardiography

研究概览

简要总结

The purpose of this study is to determine the prevalence of Fabry mutations in patients with left ventricular hypertrophy (moderate to severe), as measured by echocardiography.This study is a screening study

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • All patients over 18 years undergoing a routine echocardiography in the participating hospitals
  • Both genders will be considered.
  • Patients can be included if on 2D echocardiography the maximal septal wall thickness > 13 mm and/or the posterior wall thickness > 13 mm. The limit for inclusion is kept relatively low to detect early forms of Fabry cardiomyopathy.

排除标准

  • 未提供

结局指标

主要结局

Determination of the prevalence of Fabry mutations in patients with left ventricular hypertrophy (moderate to severe), as measured by echocardiography

时间窗: At baseline T0

patients with left ventricular hypertrophy will be screened for Fabry mutations, and results will be communicated within four months

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (9)

Loading locations...

相似试验